Evaxion Appoints New CEO
Evaxion A/S (NASDAQ: EVAX), a clinical-stage TechBio company, has appointed Dr. Helen Tayton-Martin as its new Chief Executive Officer (CEO).
Dr. Tayton-Martin will assume her new role on November 24, 2025, and step down from Evaxion's Board of Directors. She brings extensive experience, including a background in molecular immunology and an MBA from London Business School.
Dr. Helen Tayton-Martin co-founded Adaptimmune, a cancer-focused biotech company, where she served as Chief Operating Officer and later Chief Business & Strategy Officer for 17 years.
- Oversaw transatlantic growth
- Managed multiple clinical, academic, and commercial collaborations
- Secured private and public financing, including a Nasdaq IPO
Author's summary: Evaxion appoints Dr. Helen Tayton-Martin as CEO.
More News
- Bank of Canada expected to cut interest rate this week as forecasters see more weakness to come for economy
- Pirates Top 30 Prospects No. 15: Zander Mueth Set Back By Injuries
- The new age of pediatric medication awareness - Express Healthcare
- Biofuels and ethanol key to the future of U.S. agriculture - High Plains Journal
- MMJ BioPharma Cultivation: EXPOSÉ: DEA's Marijuana Licensing Scheme Exposed - MMJ BioPharma's Case Reveals DEA Contradiction Blocking FDA Approved Cannabis Medicine
- 2 US Navy aircraft crash in South China Sea
- Canada’s Lululemon Partners With National Football League
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Liam Hemsworth vs. Gabriella Brooks: Who Has the Higher Net Worth?
- D&H Distributing’s Advanced Solutions Plus Unit To Focus On The Enterprise, ‘A Pivotal Evolution’ For Its Business